Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene aberrations for precision medicine against lung adenocarcinoma.

Cancer science - 1 Jun 2016

Saito Motonobu, Shiraishi Kouya, Kunitoh Hideo, Takenoshita Seiichi, Yokota Jun, Kohno Takashi

Abstract excerpt

Lung adenocarcinoma (LADC), the most frequent histological type of lung cancer, is often triggered by an aberration in a driver oncogene in tumor cells. Examples of such aberrations are EGFR mutation and ALK fusion. Lung adenocarcinoma harboring such mutations can be treated with anticancer drugs that target the aberrant gene products. Additional oncogene aberrations, including RET, ROS1, and NRG1 fusions,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung
Share to Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Oncogenes

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 27027665
DOI: 10.1111/cas.12941
PMCID: PMC4968599

Genes

ALK
BRAF
EGFR
MET
NRG1
RET
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene aberrations for precision medicine against lung adenocarcinoma.PMID 27027665Read ↗

Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments.Semantic proximity Read ↗

NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease.Semantic proximity Read ↗

Targeted therapy for lung cancer: Beyond EGFR and ALK.Semantic proximity Read ↗

Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung CancerSemantic proximity Read ↗

The evolving paradigm of precision medicine in lung cancer.Semantic proximity Read ↗

Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.Semantic proximity Read ↗

Oncogenic alterations in advanced NSCLC: a molecular super-highwaySemantic proximity Read ↗

Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacySemantic proximity Read ↗

New Scope of Targeted Therapies in Lung Carcinoma.Semantic proximity Read ↗

Molecular Targets Beyond the Big 3.Semantic proximity Read ↗

Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.Semantic proximity Read ↗

Personalized targeted therapy for lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.